Pimasertib (PIM) versus dacarbazine (DTIC) in patients (pts) with cutaneous NRAS melanoma: a controlled, open-label phase II trial with crossover
Authors:
- 11 October 2016
- journal article
- abstracts
- Published by Elsevier in Annals of Oncology
- Vol. 27 (suppl_6) , vi389